Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.

Itzykson R, Thépot S, Quesnel B, Dreyfus F, Recher C, Wattel E, Gardin C, Adès L, Fenaux P.

Blood. 2012 Jun 21;119(25):6172-3. doi: 10.1182/blood-2012-04-422204. No abstract available.

2.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

van der Helm LH, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KS, van de Loosdrecht AA, Koedam J, Veeger NJ, Vellenga E, Huls G.

Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.

PMID:
21981697
3.

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM).

Blood. 2010 Nov 11;116(19):3735-42. doi: 10.1182/blood-2010-03-274811. Epub 2010 Jul 27.

4.

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.

Lamarque M, Raynaud S, Itzykson R, Thepot S, Quesnel B, Dreyfus F, Rauzy OB, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Visanica S, Stamatoullas A, Fenaux P, Adès L.

Blood. 2012 Dec 13;120(25):5084-5. doi: 10.1182/blood-2012-09-453555. No abstract available. Erratum in: Blood. 2014 Jun 26;123(26):4152.

5.

Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).

Bally C, Thépot S, Quesnel B, Vey N, Dreyfus F, Fadlallah J, Turlure P, de Botton S, Dartigeas C, de Renzis B, Itzykson R, Fenaux P, Adès L.

Leuk Res. 2013 Jun;37(6):637-40. doi: 10.1016/j.leukres.2013.02.014. Epub 2013 Mar 15.

PMID:
23499498
6.

Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.

Kim DY, Lee JH, Lee JH, Lee KH, Kim YK, Ahn JS, Kim HJ, Kim I, Yoon SS, Park S, Bae SH, Bang SM, Lee HG, Shin HJ, Lee JH, Min YH, Won JH, Mun YC, Oh D; Korean Society of Hematology AML/MDS Working Party.

Ann Hematol. 2010 Jan;89(1):15-23. doi: 10.1007/s00277-009-0771-1. Epub 2009 Jun 19.

PMID:
19543727
7.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Itzykson R, Thépot S, Beyne-Rauzy O, Ame S, Isnard F, Dreyfus F, Salanoubat C, Taksin AL, Chelgoum Y, Berthon C, Malfuson JV, Legros L, Vey N, Turlure P, Gardin C, Boehrer S, Ades L, Fenaux P; Groupe Francophone des Myelodysplasies (GFM).

Leuk Res. 2012 Apr;36(4):397-400. doi: 10.1016/j.leukres.2011.11.019. Epub 2011 Dec 15.

PMID:
22177456
8.

[Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].

Klepfish A, Silbershatz I, Lugassy G, Shimoni A, Mittelman M.

Harefuah. 2013 Oct;152(10):591-4, 624. Hebrew.

PMID:
24450031
9.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Itzykson R, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies(GFM).

Blood. 2011 Jan 13;117(2):403-11. doi: 10.1182/blood-2010-06-289280. Epub 2010 Oct 12.

10.

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.

Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias.

Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894.

11.

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.

Itzykson R, Thépot S, Eclache V, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Boehrer S, Gardin C, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies (GFM).

Leukemia. 2011 Jul;25(7):1207-9. doi: 10.1038/leu.2011.63. Epub 2011 Apr 5. No abstract available.

PMID:
21468040
12.

Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.

Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):711-5. doi: 10.1016/j.clml.2013.07.007. Epub 2013 Sep 17.

PMID:
24054159
13.

Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.

Fenaux P, Ades L.

Leuk Res. 2009 Dec;33 Suppl 2:S7-11. doi: 10.1016/S0145-2126(09)70227-9. Review.

PMID:
20004796
14.

Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine.

Breccia M, Salaroli A, Loglisci G, Alimena G.

Ann Hematol. 2013 Mar;92(3):411-2. doi: 10.1007/s00277-012-1581-4. Epub 2012 Sep 25. No abstract available.

PMID:
23007277
15.

Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.

Ozbalak M, Cetiner M, Bekoz H, Atesoglu EB, Ar C, Salihoglu A, Tuzuner N, Ferhanoglu B.

Hematol Oncol. 2012 Jun;30(2):76-81. doi: 10.1002/hon.986. Epub 2011 Mar 8.

PMID:
21387357
16.

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA; Cancer and Leukemia Group B.

J Clin Oncol. 2006 Aug 20;24(24):3895-903.

PMID:
16921040
17.

The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.

Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos AG, Kontos CK, Adamopoulos PG, Nakou E, Vakalopoulou S, Garypidou V, Papaioannou M, Hatjiharissi E, Papadaki HA, Spanoudakis E, Pappa V, Scorilas A, Tsatalas C, Kotsianidis I; Hellenic MDS Study Group.

Clin Cancer Res. 2016 Apr 15;22(8):1958-68. doi: 10.1158/1078-0432.CCR-15-1288. Epub 2015 Dec 23.

18.

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.

Gangatharan SA, Carney DA, Campbell LJ, Prince HM, Kenealy MK, Seymour JF.

Eur J Haematol. 2011 Aug;87(2):186-8. doi: 10.1111/j.1600-0609.2011.01653.x. No abstract available.

PMID:
21623918
19.

Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.

Falantes JF, Trujillo P, Piruat JI, Calderón C, Márquez-Malaver FJ, Martín-Antonio B, Millán A, Gómez M, González J, Martino ML, Montero I, Parody R, Espigado I, Urbano-Ispizua A, Pérez-Simón JA.

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23.

PMID:
25487600
20.

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

Prébet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C, Adès L, Quesnel B, Beach CL, Fenaux P, Vey N.

J Clin Oncol. 2011 Aug 20;29(24):3322-7. doi: 10.1200/JCO.2011.35.8135. Epub 2011 Jul 25.

Supplemental Content

Support Center